| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
10,323 |
9,792 |
$633K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,246 |
2,086 |
$118K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
329 |
311 |
$20K |
| 99406 |
|
1,222 |
1,180 |
$16K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
281 |
273 |
$14K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
251 |
244 |
$13K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
93 |
80 |
$10K |
| 96132 |
|
220 |
220 |
$9K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
539 |
521 |
$8K |
| 99215 |
Prolong outpt/office vis |
62 |
60 |
$8K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
288 |
281 |
$6K |
| 97597 |
|
180 |
177 |
$3K |
| 96138 |
|
226 |
226 |
$2K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
24 |
24 |
$2K |
| 11750 |
|
55 |
54 |
$1K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
16 |
16 |
$1K |
| 11721 |
|
115 |
115 |
$850.13 |
| G0179 |
Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care |
123 |
123 |
$766.89 |
| 36415 |
Collection of venous blood by venipuncture |
119 |
113 |
$525.57 |
| 20551 |
|
74 |
73 |
$295.54 |
| 80306 |
|
15 |
14 |
$185.33 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
213 |
212 |
$116.55 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
17 |
16 |
$68.57 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
210 |
209 |
$54.03 |
| 3074F |
|
1,711 |
1,630 |
$0.01 |
| 3079F |
|
615 |
604 |
$0.00 |
| 1125F |
|
382 |
371 |
$0.00 |
| 3075F |
|
127 |
125 |
$0.00 |
| 3080F |
|
36 |
36 |
$0.00 |
| 3008F |
|
333 |
321 |
$0.00 |
| 3078F |
|
1,548 |
1,485 |
$0.00 |
| 3077F |
|
256 |
249 |
$0.00 |
| 99072 |
|
12 |
12 |
$0.00 |